Description
Lymphoma is a commonly encountered disease in animals. While conventional chemotherapy has the potential to induce remission and improve quality of life, relapse is common and novel treatments are needed to continue to improve outcome. This review will discuss recent modifications to conventional standard of care therapy for canine and feline lymphoma that can be immediately implemented, as well as cutting-edge immunotherapy and small molecule-based approaches that are in varying stages of regulatory approval.